Condition
Breast Neoplasm Malignant Female
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 13 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
13 shownStep Count and Treatment Response in Neoadjuvant Breast CancerNCT07162675 · 2025-09-08
RECRUITINGOmission of Local Therapies in Women Patients With HER2-positive or Triple-negative Breast CancerNCT06938724 · 2025-07-25
RECRUITINGSupervised Exercise During Neoadjuvant Chemotherapy for Breast CancerNCT07764341 · 2026-09-01
NOT_YET_RECRUITINGSafety and Performance of REGENERA Breast Implant in Women Affected by Malignant Breast Lesion Treated by LumpectomyNCT05941299 · 2023-09-29
ACTIVE_NOT_RECRUITINGStudy of the Impact of DPD Activity on the Efficacy of CapecitabineNCT04198727 · 2020-07-20
ACTIVE_NOT_RECRUITINGUse of Microporous Polysaccharide Hemispheres in Breast Cancer Patients Undergoing MastectomyNCT06824831 · 2020-06-01
COMPLETEDSBRT for Breast Cancer OligometastasesNCT04424732 · 2020-06-01
UNKNOWNInterest of Touch-massage in Hospital Day CareNCT04348955 · 2019-10-07
COMPLETEDPD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast CancerNCT05812326 · 2019-05-17
COMPLETEDControlled Ovarian Stimulation in Newly Diagnosed Breast Cancer PatiEnts (fAMHOPE)NCT04289805 · 2019-02-25
TERMINATEDStudy Evaluating the Impact of Electronic Surveys on Patient-physician Communication and Quality of Life in Breast Cancer PatientsNCT03525990 · 2018-01-10
COMPLETEDOlaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC)NCT03109080 · 2017-07-24
COMPLETEDExpanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009NCT05134922
AVAILABLECommon interventions
AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cellsDRUG1CapecitabineDRUG1DPD activity assessmentOTHER1GedatolisibDRUG1Huawei Fit 2 SmartwatchDEVICE1LetrozoleDRUG1OlaparibDRUG1Omission of local therapiesOTHER1Patients DO NOT receive microporous polysaccharide hemospheres.DRUG1Patients receive microporous polysaccharide hemospheres.DRUG1QuestionnairesOTHER1Radiation therapyRADIATION1REGENERA breast implant implantationDEVICE1standard-stimulated cohortOTHER1Stereotactic Body RadiotherapyRADIATION1Supervised exerciseOTHER1Women between 18 and 70 years old with an adjuvant breast cancer histologically characterizedBEHAVIORAL1
Leading sponsors
Ankara Etlik City Hospital
1
Celcuity Inc
1
Centre Antoine Lacassagne
1
Dr. Vera Trommet
1
Erasme University Hospital
1
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
1
Fundación para la Investigación del Hospital Clínico de Valencia
1
Institut Cancerologie de l'Ouest
1
Institut Curie
1
King Hamad University Hospital, Bahrain
1
King Hussein Cancer Center
1
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
1
Tensive SRL
1
Trial status mix
COMPLETED5
ACTIVE_NOT_RECRUITING2
RECRUITING2
AVAILABLE1
NOT_YET_RECRUITING1
TERMINATED1
UNKNOWN1
Phase mix
NA4
PHASE23
PHASE12
PHASE42
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.